HIV/AIDS Topics HIV Treatment Salvage/Rescue Therapy
CROI: Tenofovir Pro-drug GS-7340 Shows Good Efficacy, Safety, and Suitability for Coformulation
- Details
- Category: Experimental HIV Drugs
- Published on Thursday, 08 March 2012 00:00
- Written by Liz Highleyman
GS-7340, a pro-drug of tenofovir that reaches higher concentrations in cells, was shown to have superior efficacy and may be more suitable for inclusion in coformulated regimens, researchers reported at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this week in Seattle.
Dolutegravir Expanded Access Begins, but Advocates Urge Caution
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 06 March 2012 00:00
- Written by Liz Highleyman
ViiV Healthcare and Shionogi have opened an expanded access program (EAP) for their investigational HIV integrase inhibitor dolutegravir for treatment-experienced patients. The drug offers a new option for people with extensively drug-resistant virus, but activists caution that dolutegravir should not be used as a single active agent, as this could lead to resistance that limits its usefulness.
Partially Active NRTIs Can Improve Response to Raltegravir for Salvage Therapy
- Details
- Category: Salvage/Rescue Therapy
- Published on Friday, 25 February 2011 00:44
- Written by Liz Highleyman
Using nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) along with raltegravir (Isentress) -- even if HIV has developed some degree of resistance to them -- leads to better outcomes for individuals who require "salvage therapy," according to a study report in the January 28, 2011, advance online edition of the Journal of Acquired Immune Deficiency Syndromes.
ICAAC: Omitting Inactive NRTIs from Salvage Regimen Can Maintain Viral Suppression
- Details
- Category: HIV Treatment
- Published on Friday, 30 September 2011 00:00
- Written by Liz Highleyman
Simplifying therapy by discontinuing nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that no longer demonstrate activity against HIV due to resistance appears to be a safe strategy that does not compromise virological control, according to a study presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) this month in Chicago.
Web Design and Development by